A Phase 1b, Open-label, Dose-escalation Study to Evaluate the Safety and Tolerability of SGN-75 in Combination With Everolimus in Patients With CD70-positive Metastatic Renal Cell Carcinoma
This is a phase 1, open-label, dose-escalation clinical trial to evaluate the safety of SGN-75 in combination with everolimus in patients with CD70-positive metastatic renal cell carcinoma.
Stanford is not currently accepting new patients for this trial. You may want to check clinicaltrials.gov to see if other locations are recruiting.
- drug : everolimus
- drug : SGN-75
Phase: Phase 1
Ages Eligible For Study:
- Diagnosis of metastatic renal cell carcinoma with confirmed CD70 expression - Previously treated with at least 1 tyrosine kinase inhibitor (TKI) - Measurable disease - Eastern Cooperative Oncology Group performance status 0 or 1 - Adequate lung and renal function